Recurrent Scalp Myxoid Neurothekeoma in a 7-year-old girl. Case Report of Uncommon Tumor and Brief Review of the Literature

Viviana Crespo¹, Alan Bencosme², Clifford Davis¹, Jodie Simelda¹, Haden Morton¹, Phillip Pearson³
Racquel Kaizer¹, Jessica Jahoda²,⁵ and Mohamed Aziz²*

¹American University of the Caribbean School of Medicine USA
²Florida Atlantic University, Wilkes Honors College, Florida, USA
³Philadelphia College of Osteopathic Medicine, Georgia, Dept. of Biomedical Sciences, USA
⁴Adventhealth Redmond, Internal Medicine Dep. Rome, Georgia, USA
⁵Research Writing & Publication (RWP), LLC, NY, USA

Abstract
Neurothekeomas are uncommon benign superficial cutaneous tumors with various histologic patterns, such as myxoid, cellular, or mixed types, depending primarily on the quantity of myxoid matrix present. They generally affect the head and neck, are more common in women than men, and typically start in the second and early third decades of life. Once believed to originate from the nerve sheath, the source is now thought to be fibroblasts that can differentiate into myofibroblasts and entice histiocytes. Neurothekeomas can present a significant challenge for pathologists to diagnose, and strict histomorphologic features and immunohistochemistry studies are essential to establish the diagnosis. We present a recurrent scalp myxoid Neurothekeoma case in a 7-year-old girl and review the pertinent literature.

Keywords: Neurothekeoma, Myxoid, Mixed, Cutaneous, Benign, Differential diagnosis

INTRODUCTION
Neurothekeoma (NT) is an uncommon benign cutaneous tumor with an ambiguous pathophysiology and many diagnostic challenges [1]. It is a rare, unique, benign soft tissue neoplasm that can be cutaneous or superficial, and it typically develops in the head and neck, shoulder, or upper extremities. Although it is likely that the cellular lineage of cellular Neurothekeoma is fibroblastic/myo-fibroblastic or fibro-histiocytic, the histogenesis of the tumor is undetermined. [2]. NT becomes increasingly prevalent in the second decade of life [3]. The median age upon diagnosis is 17 years; 25% of cases involve patients under the age of 10, 59% under the age of 20, and 80% under the age of 30 [3, 4, 5]. The 2:1 ratio in females may be explained by identifying local trauma and estrogen use as triggering variables [3, 6]. Because of overlapping clinical presentation and histology, nerve sheath myxoma has been inadvertently included within the myxoid variant of Neurothekeoma. However, Neurothekeoma as described by Barnhill and Mihm in 1990, appears to be a separate and distinct entity from true nerve sheath myxoma [7].

CASE PRESENTATION
A 7-year-old girl presented with a recurrent right frontal scalp mass. There were two prior excisions of masses at the same site during the last three years. The first excision was diagnosed as scalp nodular fasciitis, and the first recurrence was diagnosed as scalp myxoma. The parents were concerned about the frequent recurrences in three years and brought their daughter to our cancer center for evaluation. Scalp examination was significant for a pink, brown, tan, well-circumscribed soft to rubbery subcutaneous lobular nodule measuring 1.8 x 1.5 x 0.8 cm. Although the nodule was generally soft, the margins were indurated and appeared to infiltrate the scalp tissue. The nodule was slightly tender. The parents reported no other significant medical history of the patient or other family members. Imaging studies, including CT scans, were inconclusive. A decision was made to excise the entire mass with adequate, safe margins and the use of skin grafts.

Microscopic examination showed that the lesion is made up of a proliferation of epithelioid and satellite cells that ranges from faintly nodular to solid in appearance in a myxoid
background. The tumor cells showed mostly pink eosinophilic cytoplasm and round to oval nuclei with small micronuclei. Scattered pleomorphic and hyperchromatic atypical cells were mixed with more typical tumor cells. Although the tumor showed increased cellularity and focal nuclear atypia, there was no significant morphologic nuclear atypia to support a myxoid variant of sarcoma (Figure 1 A-B). By immunohistochemistry (IHC), the tumor cells were positive for vimentin, CD10, Mit-F, and focal reactivity was noted for smooth muscle actin (SMA) and CD68. They were negative for S100, glial fibrillary acidic protein (GFAP), desmin, CD34, Pan cytokeratin, MUC4, and Melan A (Figures 2 A-B). Slides from prior excisions were examined; although they showed similar features to the current recurrence, the present tumor was much more cellular. Although S-100 and GFAB immunostaining were reported positive in prior excision, the staining was equivocal and insufficient for a definitive determination; the tumor was also focally seen at one of the margins. We received the case in a consultation, and paraffin blocks were unavailable for additional studies. Equivocal staining resulted from an attempt to destain the H&E slides and restain them with S-100. Low-grade fibromyxoid sarcoma was less likely, as they are usually positive for only vimentin and MUC4.

---

**Figure 1** Microscopic examination of the mass  
1A: The lesion is made up of a proliferation of epithelioid-like and satellite cells that ranges from faintly nodular to solid in appearance in a myxoid background (H&E Stain X20).  
1B: The tumor cells showed mostly pink eosinophilic cytoplasm and round to oval nuclei with small micronuclei (H&E Stain X60).

---

**Figure 2** Immunohistochemistry studies on the mass  
2A: Tumor cells positive for Mit-F  
2B: Tumor cells positive for CD10
In addition, myxoid Dermatofibrosarcoma Protubersans (DFSP) is typically positive for vimentin and CD34. The proliferation study showed only 2% staining with Ki-67. The tumor cells were morphologically consistent with other types of sarcomas due to limited nuclear atypia and low Ki-67. The dense induration at the tumor's margins was explained as prominent scarring from the prior two excisions.

The family requested molecular testing, which produced no significant findings, and the myxoid type of sarcomas was ruled out. Surgical margins were adequate with more than 1 cm safe margin. The final diagnosis rendered was cellular myxoid Neurothekeoma. The patient was followed up for 39 months with no evidence of recurrence.

DISCUSSION

Neurothekeoma is a rare benign skin tumor with Schwann cells and perineural cells in a myxoid matrix [8]. These lesions usually present as a dome-shaped, subcutaneous papule or nodule less than 2 cm in size. They may be flesh-colored, pink-tan, or red-brown [4]. Most lesions are asymptomatic, but some may present with tenderness on palpation. Lesions are superficial and often grow slowly [4]. The head and neck are commonly involved, sometimes presenting on the shoulder or upper extremities, but rarely deeper subcutaneous fat, skeletal muscle, or mucosa [5]. The myxoid variant clinically presents as solitary, asymptomatic nodules frequently mistaken for dermal nevi or adnexal neoplasms [9].

Neurothekeomas have been classified into three pathologic variants: cellular, myxoid, and mixed, depending on how much myxoid matrix is present [8]. Generally, neurothekeomas are lobular to plexiform masses containing spindle or stellate-shaped cells with an abundant myxoid matrix [10]. The myxoid type is well-circumscribed, has poor cellularity, a high degree of myxomatous alterations, and scattered spindle cells [11]. Tumor cells are often positive for neurogenic cell markers, such as S100, GFAP, and NGFR proteins [9]. However, the myxoid variant is typically positive for NK1/C3 and negative for S100, distinguishing it from Neurothekeoma [19]. Cellular neurothekeoma also show positive nuclear staining for TFE3 without gene rearrangement or amplification on FISH, which can help differentiate it from other fibrohistiocytic and malignant granular cell tumors, which also stain positive for CD63 [12]. PRAME (preferentially expressed antigen in melanoma) expression varies between 10% to 75% in all cellular neurothekeomas investigated, making it less reliable in diagnosing malignant melanocytic tumors [15].

Microarray analysis confirmed the fibrohistiocytic origin of neurothekeomas and showed a gene expression profile distinct from nerve sheath myxomas and schwannomas, which have peripheral nerve sheath origin [19]. The molecular profile of neurothekeomas is more closely related to fibrous histiocytomas, which also have similar histological and clinical characteristics [19]. They differentially expressed collagen protein genes, whereas nerve sheath myxomas and schwannomas expressed genes that coded for cell adhesion molecules and neuronal cell intercellular signaling [19]. Point mutations on carcinogenic genes P13K, ALK, SM0, and ERBB3 have been identified using next-generation sequencing [13].

The primary means of treating Neurothekeoma is Surgical Excision [20]. While there is no agreed-upon standard for excision margin, clear microscopic margins and 2-3 mm of grossly negative margins are considered adequate [8]. Advanced techniques can be regarded as if the Neurothekeoma appears in a cosmetically sensitive area such as the face. Mohs surgery is a surgical technique that removes the tissue one layer at a time, examining each layer under a microscope until only healthy tissue remains [20]. This technique can enhance the quality of...
life in Neurothekeoma patients with tumors in these trouble areas. A majority of Neurothekeomas are small and have minimal extension into surrounding tissue. However, Neurothekeomas have been reported to grow to larger sizes and display infiltration into subcutaneous fat, skeletal muscle, and even the underlying vasculature [21]. With complete excision, reported recurrence rates of Neurothekeoma are low [20].

We report an additional case of myxoid Neurothekeoma as we believe it is critical to be aware of these unusual soft tissue lesions as well as the dangers of myxoid and mixed-type Neurothekeomas, which frequently result in difficulties with diagnosis. We hope by this report we assist in preventing malignant mesenchymal tumor misdiagnoses that could have major repercussions, such as prolonged surgical therapy or radiation.

Human subjects: Ethical review and approval were not required for the study on human participants following the local legislation and institutional requirements. The paper has been sufficiently anonymized to keep the patient’s confidentiality.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that no other relationships or activities could appear to have influenced the submitted work.

Patient's consent: Patients was lost to follow-up, and all attempts to reach the patient or family member were unsuccessful. Therefore, the paper has been sufficiently anonymized to maintain patient confidentiality.

Author contributions: Study concept and design: Jessica Jahoda, Viviana Crespo, and Haden Morton. Writing the manuscript: Viviana Crespo, Alan Bencosme, Clifford Davis, Jodie Simelda, and Racquel Kaizer. Data collection: Haden Morton, Alan Bencosme and Viviana Crespo. Analysis and interpretation: Alan Bencosme and Racquel Kaizer. Reviewing and editing the manuscript: Jessica Jahoda and Mohamed Aziz. Editing, critical review, and final approval: Mohamed Aziz

Acknowledgment: Special thanks to Alisa Lu, Fadi Jamealeddin, Tallen Cavenah and Melissa Candela, for their assistance in reviewing the final manuscript.

REFERENCES


